A meta-analysis of 24 clinical trials on monoclonal antibody treatments for hypercholesterolemia pointed to significant reductions in death and MIs, a finding that likely will catch the eye of the FDA as it considers approval for these new drugs. The results were published online April 28 in the Annals of Internal Medicine.

For patients undergoing mitral valve (MV) repair, concomitant tricuspid annuloplasty was safe and effective and minimized the risk of tricuspid regurgitation, according to a retrospective analysis.

Heart Success has single-digit 30-day readmission rates for heart failure. Here is how it meets that challenge.

As an early career electrophysiologist, Richard I. Fogel, MD, learned to raise his hand when projects needed a captain. Now he’s CEO of the St. Vincent Medical Group in Indianapolis and president of the Heart Rhythm Society (HRS). His formula? Listen, ask good questions, surround yourself with talented people and let them do their jobs, he explains in a Q&A with Cardiovascular Business.

Some implantable cardiac devices capture data that may indicate worsening health in patients with heart failure. Cardiologists are beginning to use that information to identify at-risk patients and intervene before their conditions deteriorate and require hospitalization.

Early discharge of patients who underwent transcatheter aortic valve replacement (TAVR) using a Sapien XT valve was safe and feasible, according to a single-center study. The hospital has managed to cut the mean length of stay in transfemoral cases by almost half.

Children who remained unconscious after out-of-hospital cardiac arrest had similar survival rates and cognitive functioning if they received therapeutic hypothermia or therapeutic normothermia, according to a randomized trial.

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for idarucizumab, which is being investigated to specifically reverse the anticoagulant effect of dabigatran, the active ingredient in Pradaxa® (dabigatran etexilate mesylate) in patients needing emergency intervention or experiencing an uncontrolled or life-threatening bleeding event. The idarucizumab BLA will be reviewed under Accelerated Approval and is the first review for a reversal agent in the novel oral anticoagulant (NOAC) class. Currently, no NOACs have an approved reversal agent.